<DOC>
	<DOCNO>NCT02162771</DOCNO>
	<brief_summary>This study Phase 1/3 prospective , randomised , parallel-group , active control , double blind , multicentre , international study 2 coprimary endpoint design demonstrate equivalence pharmacokinetics ( Part 1 ) , well noninferiority efficacy ( Part 2 ) , CT-P10 Rituxan coadministered CVP ass efficacy safety patient advance ( stage III-IV ) FL . Part 1 Part 2 study run parallel .</brief_summary>
	<brief_title>To Demonstrate Equivalence Pharmacokinetics Noninferiority Efficacy CT-P10 Comparison With Rituxan</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patient male female old 18 year . 2 . Patient histologically confirm FL accord World Health Organization 2008 classification ( Jaffe 2009 ) ; grade 1 3a base local laboratory review . 3 . Patient least 1 measurable tumour mass previously irradiate , mass must : great 1.5 cm long dimension 1.1 1.5 cm long dimension great 1.0 cm shortest axis 4 . Patient confirm CD20+ lymphoma , assess local laboratory review . ( Tissue obtain within 6 month Day 1 Cycle 1 review central independent reviewer detect pathological type . ) 5 . Patient Ann Arbor stage III IV disease . 1 . Patient receive rituximab ( rituximab biosimilar ) , cyclophosphamide , vincristine . 2 . Patient allergy hypersensitivity murine , chimeric , human humanise protein , cyclophosphamide , vincristine , prednisone . 3 . Patient evidence histological transformation highgrade diffuse large Bcell lymphoma . 4 . Patient known central nervous system involvement . 5 . Patient receive previous treatment NHL : Previous treatment include chemotherapy , radiotherapy , immunotherapy , and/or surgery ( except previous biopsy ) All dos corticoid therapy treatment NHL Corticoid therapy previous 4 week Day 1 Cycle 1 prednisone &gt; 20 mg per day treatment purpose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Advanced Follicular Lymphoma</keyword>
</DOC>